Please login to the form below

Not currently logged in
Email:
Password:

Envision Pharma acquires Alligent Biopharm Consulting

Aims to further optimise medical communications
Alligent Logo

Envision pharma has acquired Alligent Biopharm Consulting, a leading medical affairs agency that develops medical communications solutions for the biopharma industry.

The deal was supported by the Halifax Group, which partnered with Envision management to provide the equity investment to facilitate the acquisition. 

Brian Hepburn, CEO at Envision, said: “The addition of Alligent to the Envision Pharma Group further cements our core tenet of becoming the leading international medical affairs agency.

“By acquiring Alligent, we are able to expand the capabilities we offer to medical affairs teams to ensure optimal evidence communication and ultimate product adoption based on scientific rigor.”

Alligent's two principals, Joe Kohles and David Thompson in a joint statement, said: “Our focus on medical strategy, coupled with Envision's global presence and technology leadership position, offers the potential for us to expand and enrich our service breadth and offering to current and future clients alike.

“We look forward to joining the Group's leadership team and contributing to the continued success of both Alligent and Envision.” 

11th September 2015

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....